Fact based stock research
Intercept Pharmaceuticals (NasdaqGS:ICPT)


Intercept Pharmaceuticals stock research in summary

interceptpharma.com


Intercept Pharmaceuticals shares have a BUY rating. They show above average growth and are good value, but are riskily financed. We recommend buying and holding Intercept Pharmaceuticals shares.


Latest Obermatt Ranks


Country USA
Industry Biotechnology
Index NASDAQ
Size class Small

August 23, 2018. Top 10 stocks updated on Top 10 schedule or at least quarterly. ()


Research History: Intercept Pharmaceuticals

RESEARCH HISTORY 2015 2016 2017 2018
VALUE
VALUE
GROWTH
GROWTH
SAFETY
SAFETY
COMBINED
COMBINED

Last update of Combined Rank: 23-Aug-2018. Stock research history is based on the Obermatt Method. The higher the rank, the better is Intercept Pharmaceuticals in the corresponding investment strategy.


Value Metrics in Detail

VALUE METRICS 2015 2016 2017 2018
PRICE VS. REVENUES (P/S)
PRICE VS. REVENUES (P/S)
PRICE VS. PROFITS (P/E)
PRICE VS. PROFITS (P/E)
PRICE VS. CAPITAL (Market-to-Book)
PRICE VS. CAPITAL (Market-to-Book)
DIVIDEND YIELD
DIVIDEND YIELD
CONSOLIDATED RANK: VALUE
CONSOLIDATED RANK: VALUE

Last update of Value Rank: 23-Aug-2018. Stock analysis on value ratios: The higher the rank, the lower the value ratio of Intercept Pharmaceuticals; except for dividend yield where the rank is higher, the higher the yield.


Growth Metrics in Detail

GROWTH METRICS 2015 2016 2017 2018
REVENUE GROWTH
REVENUE GROWTH
PROFIT GROWTH
PROFIT GROWTH
STOCK RETURNS
STOCK RETURNS
CONSOLIDATED RANK: GROWTH
CONSOLIDATED RANK: GROWTH

Financial reporting date of Growth Rank: 31-Mar-2018. Stock analysis on growth metrics: The higher the rank, the higher the growth and returns of Intercept Pharmaceuticals.


Safety Metrics in Detail

SAFETY METRICS 2015 2016 2017 2018
LEVERAGE
LEVERAGE
REFINANCING
REFINANCING
LIQUIDITY
LIQUIDITY
CONSOLIDATED RANK: SAFETY
CONSOLIDATED RANK: SAFETY

Financial reporting date of Safety Rank: 31-Mar-2018. Stock analysis on safety metrics: The higher the rank, the lower the leverage of Intercept Pharmaceuticals and the more cash is available to service its debt.


Stock analysis by the purely financial fact-based Obermatt Method for the investment strategies Value, Growth and Safety for Intercept Pharmaceuticals from August 23, 2018.